Companies › MRM Health
2 active drug programs in 2 registered trials: 2 Phase 2; Immunology; next expected readout Sep 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| High-dose MH002 Live biotherapeutic product containing 6 wildtype commensal bacterial strains | – | Phase 2 | Colitis, Ulcerative | Sep 2027 |
| Low-dose MH002 Live biotherapeutic product containing 6 wildtype commensal bacterial strains | – | Phase 2 | Colitis, Ulcerative | Sep 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07296315 | Low-dose MH002 | Phase 2 | Colitis, Ulcerative | Immunology | Sep 2027 |
| NCT07296315 | High-dose MH002 | Phase 2 | Colitis, Ulcerative | Immunology | Sep 2027 |
No annotated target.
–
Triveni Bio Citryll Toll Biotech Co. Ltd. (Beijing) Ventus Therapeutics U.S. Navigator Medicines
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.